secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001104659-24-089325
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics reports Q3 FY2024 adjusted net loss $19.2M; EU/UK approval for LYTENAVA
--------------------------------------------------------------------------------

- GAAP net income $44.4M ($1.91 basic EPS), but diluted loss $0.89; adjusted net loss $19.2M ($0.83).
- Cash and equivalents $32.0M at June 30, 2024; raised $65M from private placements in March/April.
- EU and UK granted marketing authorization for LYTENAVA (bevacizumab gamma) for wet AMD.
- NORSE EIGHT trial enrollment at 359 of ~400 subjects; topline results expected Q4 CY2024.
- BLA resubmission for ONS-5010 on track for Q1 CY2025; US launch anticipated H2 CY2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465924089325/0001104659-24-089325-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465924089325/tm2421547d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-089325

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer